Product Overview

Daflora 10 contains Dapagliflozin, a selective Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitor indicated for the management of Type 2 Diabetes Mellitus. It helps improve glycemic control by reducing glucose reabsorption in the kidneys, allowing excess glucose to be eliminated through urine. In addition to effective blood glucose management, Dapagliflozin has demonstrated benefits in supporting cardiovascular and renal health in eligible patients, making it an important component of modern diabetes care.

Daflora 10 is commonly prescribed alongside a healthy diet and regular physical activity and may be used alone or in combination with other antidiabetic medications, including metformin, insulin, or other oral hypoglycemic agents. Its once-daily dosing offers convenience while supporting long-term diabetes management and improving patient adherence to therapy.

Manufactured under stringent pharmaceutical quality standards, Daflora 10 delivers consistent efficacy, safety, and reliability, helping healthcare professionals provide comprehensive treatment for patients with Type 2 Diabetes Mellitus.

How It Works

Dapagliflozin selectively inhibits the Sodium-Glucose Co-Transporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption into the bloodstream. This mechanism increases urinary glucose excretion, lowers blood glucose levels independently of insulin, and supports improved glycemic control. It may also contribute to modest weight reduction and blood pressure improvement while offering cardiovascular and renal protective benefits in appropriate patients.

Therapeutic Applications

Daflora 10 may be prescribed for the management of:

• Type 2 Diabetes Mellitus
• Blood Glucose Control
• Heart Failure (in appropriate patients)
• Chronic Kidney Disease (CKD) (as clinically indicated)
• Cardiovascular Risk Reduction in eligible patients
• Combination Therapy with other antidiabetic medications

Key Benefits

• Effectively lowers blood glucose levels.
• Once-daily oral therapy for improved convenience.
• Promotes urinary glucose excretion independent of insulin.
• Supports cardiovascular and renal health in appropriate patients.
• May assist with modest weight and blood pressure reduction.
• Manufactured under stringent pharmaceutical quality standards.

Quality Commitment

Vinix Biopharma is committed to delivering high-quality antidiabetic medicines manufactured in accordance with stringent pharmaceutical quality standards. Daflora 10 undergoes comprehensive quality assurance and rigorous testing to ensure safety, efficacy, consistency, and reliability. Every batch is carefully evaluated to maintain product integrity and support optimal patient care.

Storage Information

Store in a cool, dry place below 30°C. Protect from moisture and direct sunlight. Keep out of reach of children.

Disclaimer

Daflora 10 should be used only under the supervision of a qualified healthcare professional. Dosage and duration of treatment should be determined by the treating physician based on the patient’s clinical condition, medical history, and therapeutic requirements.